June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Orbital Retinoblastoma: Enucleation vs. Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma
Author Affiliations & Notes
  • Nicolas Alessandro Yannuzzi
    Ophthalmology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Jasmine H Francis
    Ophthalmology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Brian P Marr
    Ophthalmology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Irina Belinsky
    Ophthalmology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Ira Dunkel
    Ophthalmology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Y. Pierre Gobin
    Interventional Radiology, Weill Cornell Medical College, New York, NY
  • David H Abramson
    Ophthalmology, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Footnotes
    Commercial Relationships Nicolas Yannuzzi, None; Jasmine Francis, None; Brian Marr, None; Irina Belinsky, None; Ira Dunkel, None; Y. Pierre Gobin, None; David Abramson, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 85. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicolas Alessandro Yannuzzi, Jasmine H Francis, Brian P Marr, Irina Belinsky, Ira Dunkel, Y. Pierre Gobin, David H Abramson; Orbital Retinoblastoma: Enucleation vs. Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):85.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine the incidence of orbital recurrence following enucleation and ophthalmic artery chemosurgery (OAC) as primary treatments for advanced stage retinoblastoma.

Methods: Single center retrospective study of 73 patients (74 eyes) of Reese-Ellsworth group V, or International Classification of Retinoblastoma group D or E primarily treated with enucleation and 76 patients (90 eyes) primarily treated with OAC. Endpoints analyzed were the development of orbital disease, incidence of metastasis, and death from metastatic retinoblastoma.

Results: There were 6 orbital recurrences (incidence 8.1%) in the in the primary enucleation group and 1 orbital recurrence (incidence 1.1%) in the primary OAC group during median follow up times of 32.2 months (range 0.1-97.1) and 36.8 months (range 3.0-104.3) respectively. The 24-month Kaplan Meier estimate for orbital recurrence free survival was significantly worse for the enucleation group 92.6% (95% C.I. 83.2-96.8) than for the OAC group 98.5% (95% C.I. 89.9-99.7), Log-Rank p-value = 0.02. The enucleation group had 6 cases of metastatic disease and 2 deaths representing 8.2% and 2.7% of patients respectively. In the OAC group, there were 3 (3.9%) cases of metastatic disease and 0 deaths. Kaplan Meier analysis of metastasis free survival and overall survival yielded no statistically significant differences between the two treatment groups. Analysis of a large number of features of the two groups suggested no difference except more rubeotic eyes in the enucleated group (24%) than in the OAC group (6%).

Conclusions: In this single institution retrospective study of advanced intraocular retinoblastoma there was significantly more orbital retinoblastoma in the primarily enucleated group. OAC for advanced intraocular retinoblastoma does not increase the chance of orbital recurrence or metastatic disease compared to primary enucleation.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×